2018
DOI: 10.1016/j.jpain.2018.05.008
|View full text |Cite
|
Sign up to set email alerts
|

The Relationship of Endocannabinoidome Lipid Mediators With Pain and Psychological Stress in Women With Fibromyalgia: A Case-Control Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
45
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 33 publications
(45 citation statements)
references
References 55 publications
0
45
0
Order By: Relevance
“…123 Palmitoylethanolamide blood levels also increase in pain processing disorders such as fibromyalgia and in individuals with widespread pain. 124,125 There have been multiple prospective observational and randomized PEA trials that have been largely used as an add-on analgesic nutraceutical (Table 1). We found 19 studies and 5 randomized controlled trials (RCTs).…”
Section: Painmentioning
confidence: 99%
“…123 Palmitoylethanolamide blood levels also increase in pain processing disorders such as fibromyalgia and in individuals with widespread pain. 124,125 There have been multiple prospective observational and randomized PEA trials that have been largely used as an add-on analgesic nutraceutical (Table 1). We found 19 studies and 5 randomized controlled trials (RCTs).…”
Section: Painmentioning
confidence: 99%
“…There is increasing evidence that not only central mechanisms are essential for the presentation and the maintenance of the clinical picture in FM patients. Hence, in addition to the studies reporting central alterations (e.g., anatomical and functional changes in the brain, activation of glia cells, opioidergic dysregulation, impaired top-down modulation and nociception-driven amplification of neural signalling), several studies have shown systemic and peripheral changes in FM, e.g., regarding cytokine profile 11 13 , inflammatory lipids 14 , alteration of different metabolites and changes of the gut microbiota 15 17 , and altered protein changes in muscles 18 20 . So far, no clinically validated biomarkers for FM have been established.…”
Section: Introductionmentioning
confidence: 99%
“…26 Moreover, PEA has been reported to inhibit glutamate release in rat cerebrocortical nerve terminals. 27 Previously, we compared alterations of circulating levels of eCBs and NAEs 28,29 and glutamate 30 in subjects with chronic widespread pain and healthy controls (HC); however, no clear biological roles of this alteration were determined. Here, we investigate the effect of a 30-min dynamic load arm cycling intervention with respect to circulating levels of eCBs, NAEs and glutamate in subjects with chronic neck and shoulder pain (CNSP) and in HC.…”
Section: Introductionmentioning
confidence: 99%